Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment publishing date : 2021 - 09 - 08 save search
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-102 for the Treatment of Rett Syndrome
Published: 2021-09-08 (Crawled : 21:00) - biospace.com/
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
|
| O: -0.32%
H: 1.3%
C: -7.81%
treatment gene therapies gene therapy syndros therapy rett syndrome tsha-102
Allergy Treatment Market Size to Reach Revenues of USD 28.83 Billion by 2026 - Arizton
Published: 2021-09-08 (Crawled : 17:00) - prnewswire.com
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: 3.7%
H: 6.42%
C: 5.1%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.41%
H: 0.79%
C: 0.16%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -1.17%
H: 0.43%
C: 0.15%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -2.48%
H: 0.16%
C: -0.32%
treatment
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment of Focal-Onset Seizures in Adults Anticipated in 2021
Published: 2021-09-08 (Crawled : 14:00) - biospace.com/
XENE | $39.91 -0.99% -1.0% 360K
|
Health Technology
|
| O: 0.06%
H: 1.98%
C: -2.94%
NBIX M | $132.03 -0.39% -0.39% 560K
|
Health Technology
|
| O: -0.62%
H: 1.8%
C: 1.72%
treatment phase 2 collaboration announces collaboration trial milestone
Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease
Published: 2021-09-08 (Crawled : 13:15) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 19.11%
H: 3.61%
C: 0.85%
disease treatment positive topline parkinson
Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors
Published: 2021-09-08 (Crawled : 12:00) - globenewswire.com
BOLT | $1.12 -1.75% -1.79% 55K
|
|
| O: 0.76%
H: 0.0%
C: -7.09%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.89%
H: 0.82%
C: 0.48%
treatment solid tumors collaboration iot her2+ her2- her2
Lefamulin Receives Approval in Taiwan for Treatment of Community-Acquired Pneumonia
Published: 2021-09-08 (Crawled : 11:00) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: 4.63%
H: 2.65%
C: -0.88%
treatment acquired approval lefamulin
Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1
Published: 2021-09-08 (Crawled : 11:00) - globenewswire.com
DSGN | $3.695 -1.2% -1.22% 390K
|
Professional, Scientific, and T...
|
| O: 1.14%
H: 3.99%
C: 2.92%
disease treatment potential positive preclinical pre-clinical designation
EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation
Published: 2021-09-08 (Crawled : 11:00) - globenewswire.com
EYEG | $34.655 -0.89% 5.8K
|
Health Technology
|
| O: 0.7%
H: 0.79%
C: -9.77%
treatment phase 2 eye ocular enroll
ISA Pharmaceuticals Commences Patient Treatment in Third Phase 2 Clinical Trial with the Combination of ISA101b and Libtayo® (cemiplimab)
Published: 2021-09-08 (Crawled : 08:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -2.48%
H: 0.16%
C: -0.32%
treatment phase 2 trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.